bexarotene has been researched along with Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Angelin, M; Basu, B; Das, AV; Issac, J; Kunnummal, M; Raveendran, PS; Ravindran, S | 1 |
| Baker, R; Bissonnette, RP; Brown, PH; Dannenberg, AJ; Howe, LR; Newman, RA; Salmon, AP; Subbaramaiah, K; Yang, P; Zhou, XK | 1 |
| Berenz, A; Bissonnette, RP; Haugen, BR; Hays, WR; Janssen, J; Klopper, JP; Pugazhenthi, U; Sharma, V; Singh, M | 1 |
3 other study(ies) available for bexarotene and Carcinoma
| Article | Year |
|---|---|
RXR agonist, Bexarotene, effectively reduces drug resistance via regulation of RFX1 in embryonic carcinoma cells.
Topics: Bexarotene; Carcinoma; Cisplatin; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; NF-E2-Related Factor 2; Regulatory Factor X Transcription Factors; Regulatory Factor X1 | 2023 |
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Eicosanoids; Female; Genes, erbB-2; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Transgenic; Pyrazoles; Retinoid X Receptors; Retinoids; Substrate Specificity; Sulfonamides; Tetrahydronaphthalenes | 2008 |
In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Bexarotene; Carcinoma; Cell Line, Tumor; Humans; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2008 |